Disease · MONDO_0002522
tenosynovial giant cell tumor
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. tenosynovial giant cell tumor. Diseases, record MONDO_0002522. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002522
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
fibrous histiocytoma of tendon sheath, giant cell neoplasm of Tenosynovium, giant cell neoplasm of tendon sheath, giant cell neoplasm of the Tenosynovium, giant cell tumor of Tenosynovium, giant cell tumor of tendon sheath, giant cell tumor of the Tenosynovium, giant cell tumour of the Tenosynovium, tendon sheath giant cell neoplasm, tendon sheath giant cell tumor, tendon sheath giant cell tumour, tenosynovial giant cell neoplasm
- Open Targets
- Highest stage of its drugs
- Approval, for 2 of its 11 drugs, from DailyMed, EMA Human Drugs and FDA
- Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PEXIDARTINIB HYDROCHLORIDE | CHEMBL3989973 | Small molecule | Approval | DailyMed and FDA | 2 | 0 | 0 | Drugs and targets |
| VIMSELTINIB | CHEMBL5095202 | Small molecule | Approval | EMA Human Drugs | 1 | 0 | 0 | Drugs and targets |
| PEXIDARTINIB | CHEMBL3813873 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 3 | 3 | Drugs and targets |
| PIMICOTINIB | CHEMBL5314535 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AVELUMAB | CHEMBL3833373 | Antibody | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IVUXOLIMAB | CHEMBL4297883 | Antibody | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PD-360324 | CHEMBL2109513 | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| UTOMILUMAB | CHEMBL3707324 | Antibody | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| VIDUTOLIMOD | CHEMBL5315003 | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| EMACTUZUMAB | CHEMBL3545370 | Antibody | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets22
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CSF1R | Macrophage colony-stimulating factor 1 receptor | 3 | Macrophage colony stimulating factor receptor inhibitor | Approval | https://conductscience.org/library/genes/1436 | Drugs and targets |
| FLT3 | Receptor-type tyrosine-protein kinase FLT3 | 2 | Tyrosine-protein kinase receptor FLT3 inhibitor | Approval | https://conductscience.org/library/genes/2322 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 2 | Stem cell growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3815 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 1 | Programmed cell death 1 ligand 1 other | Phase 1/2 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| CSF1 | Macrophage colony-stimulating factor 1 | 1 | Macrophage colony-stimulating factor 1 inhibitor | Phase 1/2 | https://conductscience.org/library/genes/1435 | Drugs and targets |
| TNFRSF4 | Tumor necrosis factor receptor superfamily member 4 | 1 | Tumor necrosis factor receptor superfamily member 4 agonist | Phase 1/2 | https://conductscience.org/library/genes/7293 | Drugs and targets |
| TNFRSF9 | Tumor necrosis factor receptor superfamily member 9 | 1 | Tumor necrosis factor receptor superfamily member 9 agonist | Phase 1/2 | https://conductscience.org/library/genes/3604 | Drugs and targets |
| TUBA1A | Tubulin | 1 | Tubulin inhibitor | Phase 1 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 1 | Tubulin inhibitor | Phase 1 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 1 | Tubulin inhibitor | Phase 1 | https://conductscience.org/library/genes/84790 | Drugs and targets |
1 to 10 of 22
See all 22 targetsTrials6
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02554812 | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | Phase 1/2 | 409 | 2024-07-30 | Advanced Cancer | AVELUMAB, IVUXOLIMAB, UTOMILUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01004861 | Safety Study of PLX108-01 in Patients With Solid Tumors | Phase 1 | 132 | 2020-04-06 | Solid Tumor | PEXIDARTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02371369 | Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS) | Phase 3 | 120 | 2020-01-10 | Pigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor | PEXIDARTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03291288 | Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics) | Phase 1 | 32 | 2020-03-19 | Drug Interaction Potential | PEXIDARTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT01494688 | A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors | Phase 1 | 217 | Advanced Solid Tumors | EMACTUZUMAB, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT07499362 | Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) | Phase 2 | 20 | Tenosynovial Giant Cell Tumor | PIMICOTINIB | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Part 1: Drug-drug Interaction Phase vs Part 2: Pexidartinib Only: deaths from any cause | 1 of 30 | 0 of 25 | 55 | NCT03291288 | Trial comparisons |
| Part 1: Drug-drug Interaction Phase vs Part 2: Pexidartinib Only: serious adverse events | 5 of 30 | 5 of 25 | 55 | NCT03291288 | Trial comparisons |
Papers from its trials12
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42132251 | DERIVED | 1 | PubMed |
| 36001000 | DERIVED | 1 | PubMed |
| 34716196 | DERIVED | 1 | PubMed |
| 33289960 | DERIVED | 3 | PubMed |
| 33161240 | DERIVED | 1 | PubMed |
| 32755241 | DERIVED | 1 | PubMed |
| 31229240 | DERIVED | 1 | PubMed |
| 31114846 | DERIVED | 1 | PubMed |
| 27041409 | DERIVED | 1 | PubMed |
| 26222558 | DERIVED | 1 | PubMed |
1 to 10 of 12
See all 12 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002522
GET https://conductscience.org/api/diseases/v1/MONDO_0002522/targets?page=2